JP2013056885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013056885A5 JP2013056885A5 JP2012221161A JP2012221161A JP2013056885A5 JP 2013056885 A5 JP2013056885 A5 JP 2013056885A5 JP 2012221161 A JP2012221161 A JP 2012221161A JP 2012221161 A JP2012221161 A JP 2012221161A JP 2013056885 A5 JP2013056885 A5 JP 2013056885A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- pharmaceutical composition
- amino acid
- seq
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 150000001413 amino acids Chemical group 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 239000013598 vector Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 229930182817 methionine Natural products 0.000 claims 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75196305P | 2005-12-21 | 2005-12-21 | |
| US60/751,963 | 2005-12-21 | ||
| EP05028064.3 | 2005-12-21 | ||
| EP05028064 | 2005-12-21 | ||
| US78086106P | 2006-03-10 | 2006-03-10 | |
| US60/780,861 | 2006-03-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546272A Division JP5399712B2 (ja) | 2005-12-21 | 2006-12-21 | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013056885A JP2013056885A (ja) | 2013-03-28 |
| JP2013056885A5 true JP2013056885A5 (enExample) | 2013-07-25 |
Family
ID=40413962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546272A Expired - Fee Related JP5399712B2 (ja) | 2005-12-21 | 2006-12-21 | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| JP2012221161A Withdrawn JP2013056885A (ja) | 2005-12-21 | 2012-10-03 | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546272A Expired - Fee Related JP5399712B2 (ja) | 2005-12-21 | 2006-12-21 | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8394926B2 (enExample) |
| EP (2) | EP1976880B1 (enExample) |
| JP (2) | JP5399712B2 (enExample) |
| KR (1) | KR101287777B1 (enExample) |
| CN (1) | CN101370827B (enExample) |
| AU (1) | AU2006328886C1 (enExample) |
| BR (1) | BRPI0620632A2 (enExample) |
| CA (1) | CA2633766C (enExample) |
| CY (1) | CY1118053T1 (enExample) |
| DK (1) | DK1976880T3 (enExample) |
| ES (1) | ES2595091T3 (enExample) |
| HR (1) | HRP20161216T1 (enExample) |
| HU (1) | HUE031151T2 (enExample) |
| IL (1) | IL192277A (enExample) |
| LT (1) | LT1976880T (enExample) |
| ME (1) | ME02581B (enExample) |
| NZ (1) | NZ569204A (enExample) |
| PL (1) | PL1976880T3 (enExample) |
| PT (1) | PT1976880T (enExample) |
| RS (1) | RS55181B1 (enExample) |
| RU (2) | RU2426743C2 (enExample) |
| SG (1) | SG193141A1 (enExample) |
| WO (1) | WO2007071426A1 (enExample) |
| ZA (1) | ZA200805400B (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| PT1976880T (pt) | 2005-12-21 | 2016-09-28 | Amgen Res Munich Gmbh | Composições farmacêuticas com resistência a cea solúvel |
| US20090226444A1 (en) * | 2005-12-21 | 2009-09-10 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
| US20130035249A1 (en) * | 2009-12-01 | 2013-02-07 | Medimmune, Llc | Methods and compositions for detecting and treating cea-expressing cancers |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| WO2013012414A1 (en) * | 2011-07-18 | 2013-01-24 | Medimmune, Llc | Dosing regimens for treatment of cea-expressing cancers |
| WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP3586874A1 (en) | 2012-08-14 | 2020-01-01 | IBC Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA3169263A1 (en) | 2012-11-13 | 2014-05-22 | Astellas Pharma Inc. | Agents for treatment of claudin expressing cancer diseases |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-CEACAM5 antibodies and their applications |
| BR112015017800A2 (pt) | 2013-02-26 | 2017-11-21 | Roche Glycart Ag | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t |
| MX375359B (es) * | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| ES2753950T3 (es) | 2013-03-15 | 2020-04-15 | Amgen Res Munich Gmbh | Moléculas de unión monocatenarias que comprenden ABP del extremo N |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| WO2015166484A1 (en) | 2014-04-27 | 2015-11-05 | Ccam Therapeutics Ltd. | Humanized antibodies against ceacam1 |
| RU2016151645A (ru) | 2014-07-01 | 2018-08-03 | Пфайзер Инк. | Биспецифические гетеродимерные диантитела и их применение |
| EP3262217A4 (en) | 2015-02-24 | 2018-07-18 | BioAtla LLC | Conditionally active biological proteins |
| CN106432502B (zh) * | 2015-08-10 | 2020-10-27 | 中山大学 | 用于治疗cea阳性表达肿瘤的双特异纳米抗体 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CA2990755A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffman-La Roche Ag | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules |
| CA2997406C (en) | 2015-12-09 | 2024-05-28 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
| CN108368179B (zh) * | 2016-01-08 | 2022-08-23 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法 |
| WO2017208018A1 (en) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
| CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
| JP7125400B2 (ja) | 2016-12-19 | 2022-08-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法 |
| KR20190099527A (ko) | 2017-01-03 | 2019-08-27 | 에프. 호프만-라 로슈 아게 | 항-4-1bb 클론 20h4.9를 포함하는 이중특이성 항원 결합 분자 |
| CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
| CN107058234B (zh) * | 2017-05-12 | 2019-09-13 | 常州市第一人民医院 | Car.il-33-t及其制备与应用 |
| KR102794369B1 (ko) | 2017-08-01 | 2025-04-15 | 에이비 테라퓨틱스 인코퍼레이티드 | 이중특이 항체 및 그의 용도 |
| EP3704155A2 (en) | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Combination therapy with targeted ox40 agonists |
| EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| ES2973518T3 (es) | 2018-06-03 | 2024-06-20 | Lamkap Bio Beta Ag | Anticuerpos biespecíficos contra CEACAM5 y CD47 |
| JP2021528988A (ja) | 2018-07-04 | 2021-10-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子 |
| WO2020127618A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted agonistic cd28 antigen binding molecules |
| WO2020159918A2 (en) | 2019-01-28 | 2020-08-06 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| EP3693023A1 (en) | 2019-02-11 | 2020-08-12 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
| CN114173823A (zh) | 2019-02-07 | 2022-03-11 | 赛诺菲 | 抗ceacam5免疫缀合物用于治疗肺癌的用途 |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| KR20220034784A (ko) | 2019-06-13 | 2022-03-18 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 아미노벤즈아제핀 화합물, 면역접합체, 및 이의 용도 |
| CN114531878A (zh) * | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
| WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| CA3148694A1 (en) | 2019-09-03 | 2021-03-11 | Romas Kudirka | Aminoquinoline compounds, immunoconjugates, and uses thereof |
| PE20221045A1 (es) | 2019-09-18 | 2022-06-22 | Lamkap Bio Alpha AG | Anticuerpos biespecificos contra ceacam5 y cd3 |
| AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
| KR20220088901A (ko) | 2019-10-25 | 2022-06-28 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 티에노아제핀 면역접합체, 및 이의 용도 |
| TW202128765A (zh) * | 2019-11-21 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種雙特異性抗體 |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| EP4146282A1 (en) | 2020-05-08 | 2023-03-15 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| JP2023530109A (ja) | 2020-06-11 | 2023-07-13 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| EP4196168A1 (en) | 2020-08-13 | 2023-06-21 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| US20240238430A1 (en) | 2020-12-11 | 2024-07-18 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| KR20230121772A (ko) | 2020-12-18 | 2023-08-21 | 람카프 바이오 베타 엘티디. | Ceacam5 및 cd47에 대한 이중특이적 항체 |
| CA3212907A1 (en) | 2021-03-26 | 2022-09-29 | Gary Brandt | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| EP4313162A1 (en) | 2021-03-26 | 2024-02-07 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| CN119233830A (zh) | 2022-03-23 | 2024-12-31 | 新锐生物技术公司 | 用于靶向表达癌胚抗原的肿瘤的抗体缀合物 |
| US20250230256A1 (en) | 2022-06-16 | 2025-07-17 | Lamkap Bio Beta Ltd | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
| AU2024237581A1 (en) | 2023-03-14 | 2025-10-02 | Xencor, Inc. | Anti-cd28 compositions |
| WO2024261013A1 (en) | 2023-06-21 | 2024-12-26 | F. Hoffmann-La Roche Ag | Combination therapy with fap-targeted lymphotoxin beta receptor agonists |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| DK0561907T3 (da) | 1990-12-05 | 1999-05-31 | Novo Nordisk As | Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5910488A (en) | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| EP1071752B1 (en) | 1998-04-21 | 2003-07-09 | Micromet AG | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| AU2002233340B2 (en) | 2001-02-19 | 2008-05-22 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| RU2401843C2 (ru) | 2003-10-16 | 2010-10-20 | Микромет Аг | Полиспецифические деиммунизирующие cd3-связующие |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| PT1976880T (pt) | 2005-12-21 | 2016-09-28 | Amgen Res Munich Gmbh | Composições farmacêuticas com resistência a cea solúvel |
| US20090226444A1 (en) * | 2005-12-21 | 2009-09-10 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
-
2006
- 2006-12-21 PT PT68411123T patent/PT1976880T/pt unknown
- 2006-12-21 BR BRPI0620632-8A patent/BRPI0620632A2/pt active Search and Examination
- 2006-12-21 JP JP2008546272A patent/JP5399712B2/ja not_active Expired - Fee Related
- 2006-12-21 CA CA2633766A patent/CA2633766C/en not_active Expired - Fee Related
- 2006-12-21 ZA ZA200805400A patent/ZA200805400B/xx unknown
- 2006-12-21 RS RS20160791A patent/RS55181B1/sr unknown
- 2006-12-21 LT LTEP06841112.3T patent/LT1976880T/lt unknown
- 2006-12-21 EP EP06841112.3A patent/EP1976880B1/en active Active
- 2006-12-21 KR KR1020087017796A patent/KR101287777B1/ko not_active Expired - Fee Related
- 2006-12-21 DK DK06841112.3T patent/DK1976880T3/en active
- 2006-12-21 WO PCT/EP2006/012425 patent/WO2007071426A1/en not_active Ceased
- 2006-12-21 EP EP12167996A patent/EP2527370A1/en not_active Withdrawn
- 2006-12-21 CN CN200680052637.9A patent/CN101370827B/zh not_active Expired - Fee Related
- 2006-12-21 HU HUE06841112A patent/HUE031151T2/en unknown
- 2006-12-21 AU AU2006328886A patent/AU2006328886C1/en not_active Ceased
- 2006-12-21 ES ES06841112.3T patent/ES2595091T3/es active Active
- 2006-12-21 US US12/158,611 patent/US8394926B2/en active Active
- 2006-12-21 HR HRP20161216TT patent/HRP20161216T1/hr unknown
- 2006-12-21 NZ NZ569204A patent/NZ569204A/en not_active IP Right Cessation
- 2006-12-21 SG SG2013054853A patent/SG193141A1/en unknown
- 2006-12-21 RU RU2008129787/10A patent/RU2426743C2/ru not_active IP Right Cessation
- 2006-12-21 PL PL06841112T patent/PL1976880T3/pl unknown
-
2008
- 2008-06-18 IL IL192277A patent/IL192277A/en not_active IP Right Cessation
-
2010
- 2010-11-29 RU RU2010148652/10A patent/RU2573893C2/ru not_active IP Right Cessation
-
2012
- 2012-10-03 JP JP2012221161A patent/JP2013056885A/ja not_active Withdrawn
-
2013
- 2013-01-14 US US13/740,358 patent/US9695250B2/en active Active
-
2016
- 2016-09-19 US US15/269,680 patent/US9982063B2/en active Active
- 2016-09-23 CY CY20161100951T patent/CY1118053T1/el unknown
- 2016-12-21 ME MEP-2016-218A patent/ME02581B/me unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013056885A5 (enExample) | ||
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP7724332B2 (ja) | クローディン１８．２結合部分およびその利用 | |
| US11254746B2 (en) | Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof | |
| JP2022079549A5 (enExample) | ||
| US9115195B2 (en) | Therapeutic DLL4 binding proteins | |
| JP2021106617A5 (enExample) | ||
| RU2017122014A (ru) | Антитела к c10orf54 и их применения | |
| JP2020510422A5 (enExample) | ||
| JP7257971B2 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2018527908A5 (enExample) | ||
| JP2016509014A (ja) | 新規の多特異的構成物 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2010524435A5 (enExample) | ||
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| AU2010248365A1 (en) | Anti-AXL antibody | |
| JP2013519364A5 (enExample) | ||
| JP2014530017A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| TW201134489A (en) | Basigin binding proteins | |
| US20250129176A1 (en) | Cd19/cd38 multispecific antibodies | |
| JP2018528759A5 (enExample) | ||
| JPWO2020090892A1 (ja) | 抗ヒトＦｎ１４抗体 |